Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026
The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.